161 related articles for article (PubMed ID: 36585202)
1. Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage.
Xiao H; Wu Z; Wang Q; Zhou C; Lu F; Xiao Y
Anticancer Res; 2023 Jan; 43(1):389-403. PubMed ID: 36585202
[TBL] [Abstract][Full Text] [Related]
2. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage.
Zhang DF; Yang ZC; Chen JQ; Jin XX; Qiu YD; Chen XJ; Shi HY; Liu ZG; Wang MS; Liang G; Zheng XH
BMC Complement Med Ther; 2021 Jul; 21(1):195. PubMed ID: 34229670
[TBL] [Abstract][Full Text] [Related]
4. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer.
Chiang YC; Leu WJ; Chen YC; Ye PC; Hsu YT; Hsiao YC; Hsu JL; Chan SH; Hsu LC; Huang HS; Guh JH
Prostate; 2023 Dec; 83(16):1549-1563. PubMed ID: 37583103
[TBL] [Abstract][Full Text] [Related]
6. Flavokawain C inhibits proliferation and migration of liver cancer cells through FAK/PI3K/AKT signaling pathway.
Wang R; Li R; Yang H; Chen X; Wu L; Zheng X; Jin Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):117. PubMed ID: 38460052
[TBL] [Abstract][Full Text] [Related]
7. The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer.
Wang G; Chen X; Wang N; Xiao Y; Shu S; Alsayed AMM; Liu L; Ma Y; Liu P; Zhang Q; Chen X; Liu Z; Zheng X
Bioorg Chem; 2021 Jun; 111():104880. PubMed ID: 33839585
[TBL] [Abstract][Full Text] [Related]
8. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
9. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
[TBL] [Abstract][Full Text] [Related]
11. Pyrogallol from
Arjsri P; Mapoung S; Semmarath W; Srisawad K; Tuntiwechapikul W; Yodkeeree S; Dejkriengkraikul P
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047425
[TBL] [Abstract][Full Text] [Related]
12. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract][Full Text] [Related]
13. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
[TBL] [Abstract][Full Text] [Related]
14. DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest.
Gao K; Zhu S; Shao Q; Qi Y; Zhang C; Li X; Guo J; Wu G; Jiang H
Transl Oncol; 2023 Sep; 35():101708. PubMed ID: 37406549
[TBL] [Abstract][Full Text] [Related]
15. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
16. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
[TBL] [Abstract][Full Text] [Related]
17. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
[TBL] [Abstract][Full Text] [Related]
18. Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer.
Weng M; Shi C; Han H; Zhu H; Xiao Y; Guo H; Yu Z; Wu C
PeerJ; 2022; 10():e14042. PubMed ID: 36132221
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
You B; Zhang KC
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
